{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T20:18:41Z","timestamp":1788034721077,"version":"build-2784847793"},"reference-count":246,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Horizontal Projects","award":["2023138 and 202504137"],"award-info":[{"award-number":["2023138 and 202504137"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09198-8","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:14:32Z","timestamp":1787987672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Barrier Disruption and Immune Dysregulation to Targeted Therapies in Atopic Dermatitis"],"prefix":"10.1007","volume":"69","author":[{"given":"Xin","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"9198_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","volume":"190","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yang Y et al (2023) Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol 190:55\u201361. https:\/\/doi.org\/10.1093\/bjd\/ljad339","journal-title":"Br J Dermatol"},{"key":"9198_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/jdv.19723","volume":"38","author":"O Faye","year":"2024","unstructured":"Faye O, Flohr C, Kabashima K et al (2024) Atopic dermatitis: A global health perspective. J Eur Acad Dermatol Venereol JEADV 38:801\u2013811. https:\/\/doi.org\/10.1111\/jdv.19723","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR3","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1111\/all.15754","volume":"78","author":"E Denton","year":"2023","unstructured":"Denton E, O\u2019Hehir RE, Hew M (2023) The changing global prevalence of asthma and atopic dermatitis. Allergy 78:2079\u20132080. https:\/\/doi.org\/10.1111\/all.15754","journal-title":"Allergy"},{"key":"9198_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/jdv.19686","volume":"38","author":"X-C Cai","year":"2024","unstructured":"Cai X-C, Wang S-H, Wang C-X et al (2024) Epidemiology of mental health comorbidity in patients with atopic dermatitis: An analysis of global trends from 1998 to 2022. J Eur Acad Dermatol Venereol JEADV 38:496\u2013512. https:\/\/doi.org\/10.1111\/jdv.19686","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.anai.2025.05.003","volume":"135","author":"S Narla","year":"2025","unstructured":"Narla S, Silverberg JI (2025) Current updates in the epidemiology and comorbidities of atopic dermatitis. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol 135:511\u2013520. https:\/\/doi.org\/10.1016\/j.anai.2025.05.003","journal-title":"Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol"},{"key":"9198_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/ddg.15688","volume":"23","author":"H Wu","year":"2025","unstructured":"Wu H, Zhu J, Yang N et al (2025) Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 23:702\u2013710. https:\/\/doi.org\/10.1111\/ddg.15688","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG"},{"key":"9198_CR7","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.3390\/ijms23105318","volume":"23","author":"V Moosbrugger-Martinz","year":"2022","unstructured":"Moosbrugger-Martinz V, Leprince C, M\u00e9chin M-C et al (2022) Revisiting the Roles of Filaggrin in Atopic Dermatitis. Int J Mol Sci 23:5318. https:\/\/doi.org\/10.3390\/ijms23105318","journal-title":"Int J Mol Sci"},{"key":"9198_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12272-021-01305-x","volume":"44","author":"Y Kim","year":"2021","unstructured":"Kim Y, Lim K-M (2021) Skin barrier dysfunction and filaggrin. Arch Pharm Res 44:36\u201348. https:\/\/doi.org\/10.1007\/s12272-021-01305-x","journal-title":"Arch Pharm Res"},{"key":"9198_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/all.15582","volume":"78","author":"H Jeong","year":"2023","unstructured":"Jeong H, Lee N, Uhm C et al (2023) RAB25 coordinates filaggrin-containing keratohyalin granule maturation and affects atopic dermatitis severity. Allergy 78:1007\u20131019. https:\/\/doi.org\/10.1111\/all.15582","journal-title":"Allergy"},{"key":"9198_CR10","doi-asserted-by":"publisher","unstructured":"D\u2019Avino P, Kim J, Li M et al (2025) Distinct Roles of IL-4, IL-13, and IL-22 in Human Skin Barrier Dysfunction and Atopic Dermatitis. https:\/\/doi.org\/10.1111\/all.70060. Allergy","DOI":"10.1111\/all.70060"},{"key":"9198_CR11","doi-asserted-by":"publisher","first-page":"1361005","DOI":"10.3389\/fimmu.2024.1361005","volume":"15","author":"M Afshari","year":"2024","unstructured":"Afshari M, Kolackova M, Rosecka M et al (2024) Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches. Front Immunol 15:1361005. https:\/\/doi.org\/10.3389\/fimmu.2024.1361005","journal-title":"Front Immunol"},{"key":"9198_CR12","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.3390\/pharmaceutics14122753","volume":"14","author":"AM L\u00e9","year":"2022","unstructured":"L\u00e9 AM, Torres T (2022) OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis\u2014Focus on Rocatinlimab and Amlitelimab. Pharmaceutics 14:2753. https:\/\/doi.org\/10.3390\/pharmaceutics14122753","journal-title":"Pharmaceutics"},{"key":"9198_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","volume":"25","author":"M Croft","year":"2024","unstructured":"Croft M, Esfandiari E, Chong C et al (2024) OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. Am J Clin Dermatol 25:447\u2013461. https:\/\/doi.org\/10.1007\/s40257-023-00838-9","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR14","doi-asserted-by":"publisher","first-page":"154318","DOI":"10.1016\/j.phymed.2022.154318","volume":"104","author":"HJ Kim","year":"2022","unstructured":"Kim HJ, Song H-K, Park SH et al (2022) Terminalia chebula Retz. extract ameliorates the symptoms of atopic dermatitis by regulating anti-inflammatory factors in vivo and suppressing STAT1\/3 and NF-\u0138B signaling in vitro. Phytomedicine 104:154318. https:\/\/doi.org\/10.1016\/j.phymed.2022.154318","journal-title":"Phytomedicine"},{"key":"9198_CR15","doi-asserted-by":"publisher","first-page":"e145185","DOI":"10.1172\/jci.insight.145185","volume":"6","author":"BE Kim","year":"2021","unstructured":"Kim BE, Kim J, Goleva E et al (2021) Particulate matter causes skin barrier dysfunction. JCI Insight 6:e145185. https:\/\/doi.org\/10.1172\/jci.insight.145185","journal-title":"JCI Insight"},{"key":"9198_CR16","doi-asserted-by":"publisher","first-page":"e20212397","DOI":"10.1084\/jem.20212397","volume":"219","author":"Z Qiu","year":"2022","unstructured":"Qiu Z, Zhu Z, Liu X et al (2022) A dysregulated sebum-microbial metabolite-IL-33 axis initiates skin inflammation in atopic dermatitis. J Exp Med 219:e20212397. https:\/\/doi.org\/10.1084\/jem.20212397","journal-title":"J Exp Med"},{"key":"9198_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jid.2021.05.033","volume":"142","author":"X Dai","year":"2022","unstructured":"Dai X, Shiraishi K, Muto J et al (2022) Nuclear IL-33 Plays an Important Role in IL-31\u2013Mediated Downregulation of FLG, Keratin 1, and Keratin 10 by Regulating Signal Transducer and Activator of Transcription 3 Activation in Human Keratinocytes. J Invest Dermatol 142:136\u2013144e3. https:\/\/doi.org\/10.1016\/j.jid.2021.05.033","journal-title":"J Invest Dermatol"},{"key":"9198_CR18","doi-asserted-by":"publisher","first-page":"eabi6887","DOI":"10.1126\/sciimmunol.abi6887","volume":"8","author":"MS Fassett","year":"2023","unstructured":"Fassett MS, Braz JM, Castellanos CA et al (2023) IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis. Sci Immunol 8:eabi6887. https:\/\/doi.org\/10.1126\/sciimmunol.abi6887","journal-title":"Sci Immunol"},{"key":"9198_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/bjd\/ljae138","volume":"191","author":"N Sander","year":"2024","unstructured":"Sander N, St\u00f6lzl D, Fonfara M et al (2024) Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis. Br J Dermatol 191:344\u2013350. https:\/\/doi.org\/10.1093\/bjd\/ljae138","journal-title":"Br J Dermatol"},{"key":"9198_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jaad.2025.04.027","volume":"93","author":"J-W Chang","year":"2025","unstructured":"Chang J-W, Huang X, Jiang W et al (2025) Abrocitinib versus dupilumab: Impact on skin barrier function and proteomics in atopic dermatitis. J Am Acad Dermatol 93:406\u2013414. https:\/\/doi.org\/10.1016\/j.jaad.2025.04.027","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR21","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1111\/all.15432","volume":"77","author":"E Berdyshev","year":"2022","unstructured":"Berdyshev E, Goleva E, Bissonnette R et al (2022) Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy 77:3388\u20133397. https:\/\/doi.org\/10.1111\/all.15432","journal-title":"Allergy"},{"key":"9198_CR22","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/alr.23469","volume":"14","author":"R Song","year":"2024","unstructured":"Song R, Zhang H, Liang Z (2024) Research progress in OX40\/OX40L in allergic diseases. Int Forum Allergy Rhinol 14:1921\u20131928. https:\/\/doi.org\/10.1002\/alr.23469","journal-title":"Int Forum Allergy Rhinol"},{"key":"9198_CR23","doi-asserted-by":"publisher","first-page":"eabe2749","DOI":"10.1126\/sciimmunol.abe2749","volume":"6","author":"C Bangert","year":"2021","unstructured":"Bangert C, Rindler K, Krausgruber T et al (2021) Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4R\u03b1 blockade. Sci Immunol 6:eabe2749. https:\/\/doi.org\/10.1126\/sciimmunol.abe2749","journal-title":"Sci Immunol"},{"key":"9198_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jaad.2024.03.039","volume":"91","author":"I Hasan","year":"2024","unstructured":"Hasan I, Parsons L, Duran S, Zinn Z (2024) Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study. J Am Acad Dermatol 91:255\u2013258. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.039","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/bjd.19703","volume":"185","author":"MA McAleer","year":"2021","unstructured":"McAleer MA, Jakasa I, Stefanovic N et al (2021) Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis. Br J Dermatol 185:153\u2013163. https:\/\/doi.org\/10.1111\/bjd.19703","journal-title":"Br J Dermatol"},{"key":"9198_CR26","doi-asserted-by":"publisher","first-page":"11635","DOI":"10.3390\/ijms241411635","volume":"24","author":"J Yoon","year":"2023","unstructured":"Yoon J, Lee SK, Park A et al (2023) Exosome from IFN-\u03b3-Primed Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Improved Skin Inflammation and Barrier Function. Int J Mol Sci 24:11635. https:\/\/doi.org\/10.3390\/ijms241411635","journal-title":"Int J Mol Sci"},{"key":"9198_CR27","doi-asserted-by":"publisher","first-page":"e21574","DOI":"10.1096\/fj.202002709R","volume":"35","author":"C Xiao","year":"2021","unstructured":"Xiao C, Sun Z, Gao J et al (2021) Enhanced phenotype of calcipotriol-induced atopic dermatitis in filaggrin-deficient mice. FASEB J Off Publ Fed Am Soc Exp Biol 35:e21574. https:\/\/doi.org\/10.1096\/fj.202002709R","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"9198_CR28","doi-asserted-by":"publisher","first-page":"eado1375","DOI":"10.1126\/scitranslmed.ado1375","volume":"17","author":"K Zhang","year":"2025","unstructured":"Zhang K, Kim SM, Kwon H-K et al (2025) Peripherally induced ROR\u03b3t+ skin-resident regulatory T cells mediate the efficacy of allergen-specific immunotherapy. Sci Transl Med 17:eado1375. https:\/\/doi.org\/10.1126\/scitranslmed.ado1375","journal-title":"Sci Transl Med"},{"key":"9198_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41423-025-01264-z","volume":"22","author":"Z Chen","year":"2025","unstructured":"Chen Z, Dragan M, Sun P et al (2025) The AhR-Ovol1-Id1 regulatory axis in keratinocytes promotes epidermal and immune homeostasis in atopic dermatitis-like skin inflammation. Cell Mol Immunol 22:300\u2013315. https:\/\/doi.org\/10.1038\/s41423-025-01264-z","journal-title":"Cell Mol Immunol"},{"key":"9198_CR30","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1111\/all.15035","volume":"76","author":"M Murai-Yamamura","year":"2021","unstructured":"Murai-Yamamura M, Garcet S, Yamamura K et al (2021) TH2 cytokines and Staphylococcus aureus cooperatively induce atopic dermatitis-like transcriptomes. Allergy 76:3534\u20133537. https:\/\/doi.org\/10.1111\/all.15035","journal-title":"Allergy"},{"key":"9198_CR31","doi-asserted-by":"publisher","first-page":"1726557","DOI":"10.3389\/fimmu.2025.1726557","volume":"16","author":"J Riebelmann","year":"2025","unstructured":"Riebelmann J, Kienzle N, Sauer B, Schittek B (2025) Commensal Staphylococci attenuate Staphylococcus aureus skin colonization and inflammation via AHR-dependent signaling. Front Immunol 16:1726557. https:\/\/doi.org\/10.3389\/fimmu.2025.1726557","journal-title":"Front Immunol"},{"key":"9198_CR32","doi-asserted-by":"publisher","first-page":"1098160","DOI":"10.3389\/fimmu.2023.1098160","volume":"14","author":"L Landemaine","year":"2023","unstructured":"Landemaine L, Da Costa G, Fissier E et al (2023) Staphylococcus epidermidis isolates from atopic or healthy skin have opposite effect on skin cells: potential implication of the AHR pathway modulation. Front Immunol 14:1098160. https:\/\/doi.org\/10.3389\/fimmu.2023.1098160","journal-title":"Front Immunol"},{"key":"9198_CR33","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1111\/all.15671","volume":"78","author":"A Rapin","year":"2023","unstructured":"Rapin A, Rehbinder EM, Macowan M et al (2023) The skin microbiome in the first year of life and its association with atopic dermatitis. Allergy 78:1949\u20131963. https:\/\/doi.org\/10.1111\/all.15671","journal-title":"Allergy"},{"key":"9198_CR34","doi-asserted-by":"publisher","first-page":"670637","DOI":"10.3389\/fimmu.2021.670637","volume":"12","author":"N Fu","year":"2021","unstructured":"Fu N, Xie F, Sun Z, Wang Q (2021) The OX40\/OX40L Axis Regulates T Follicular Helper Cell Differentiation: Implications for Autoimmune Diseases. Front Immunol 12:670637. https:\/\/doi.org\/10.3389\/fimmu.2021.670637","journal-title":"Front Immunol"},{"key":"9198_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","volume":"10","author":"Y Fu","year":"2020","unstructured":"Fu Y, Lin Q, Zhang Z, Zhang L (2020) Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B 10:414\u2013433. https:\/\/doi.org\/10.1016\/j.apsb.2019.08.010","journal-title":"Acta Pharm Sin B"},{"key":"9198_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41423-022-00873-2","volume":"19","author":"M Han","year":"2022","unstructured":"Han M, Ma J, Ouyang S et al (2022) The kinase p38\u03b1 functions in dendritic cells to regulate Th2-cell differentiation and allergic inflammation. Cell Mol Immunol 19:805\u2013819. https:\/\/doi.org\/10.1038\/s41423-022-00873-2","journal-title":"Cell Mol Immunol"},{"key":"9198_CR37","doi-asserted-by":"publisher","first-page":"712676","DOI":"10.3389\/fimmu.2021.712676","volume":"12","author":"Y Nishikawa","year":"2021","unstructured":"Nishikawa Y, Fukaya T, Fukui T et al (2021) Congenital Deficiency of Conventional Dendritic Cells Promotes the Development of Atopic Dermatitis-Like Inflammation. Front Immunol 12:712676. https:\/\/doi.org\/10.3389\/fimmu.2021.712676","journal-title":"Front Immunol"},{"key":"9198_CR38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/bjd\/ljae230","volume":"191","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Croft M, Geng B et al (2024) The role of OX40 ligand\/OX40 axis signalling in atopic dermatitis. Br J Dermatol 191:488\u2013496. https:\/\/doi.org\/10.1093\/bjd\/ljae230","journal-title":"Br J Dermatol"},{"key":"9198_CR39","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1111\/all.14362","volume":"75","author":"Y Yamanishi","year":"2020","unstructured":"Yamanishi Y, Mogi K, Takahashi K et al (2020) Skin-infiltrating basophils promote atopic dermatitis-like inflammation via IL-4 production in mice. Allergy 75:2613\u20132622. https:\/\/doi.org\/10.1111\/all.14362","journal-title":"Allergy"},{"key":"9198_CR40","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41420-025-02630-6","volume":"11","author":"Y Gunji","year":"2025","unstructured":"Gunji Y, Matsumura T, Karasawa T et al (2025) IL-33-primed NLRP3 inflammasome in basophils drives IL-1\u03b2 production and initiates atopic dermatitis inflammation. Cell Death Discov 11:346. https:\/\/doi.org\/10.1038\/s41420-025-02630-6","journal-title":"Cell Death Discov"},{"key":"9198_CR41","doi-asserted-by":"publisher","unstructured":"Li S, Xu D, Zhang C et al (2025) Cinobufagin Directly Targets PDE4D to Disrupt Fibroblast-Dendritic Cell Crosstalk in Atopic Dermatitis. https:\/\/doi.org\/10.1002\/advs.202501670. Adv Sci Weinh Baden-Wurtt Ger e01670","DOI":"10.1002\/advs.202501670"},{"key":"9198_CR42","doi-asserted-by":"publisher","first-page":"116114","DOI":"10.1016\/j.celrep.2025.116114","volume":"44","author":"I Imanishi","year":"2025","unstructured":"Imanishi I, Gill R, Wilder A et al (2025) A basophil-fibroblast pro-inflammatory axis fuels type 2 skin inflammation. Cell Rep 44:116114. https:\/\/doi.org\/10.1016\/j.celrep.2025.116114","journal-title":"Cell Rep"},{"key":"9198_CR43","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.jaci.2020.11.036","volume":"147","author":"JM Leyva-Castillo","year":"2021","unstructured":"Leyva-Castillo JM, Das M, Artru E et al (2021) Mast cell-derived IL-13 downregulates IL-12 production by skin dendritic cells to inhibit the TH1 cell response to cutaneous antigen exposure. J Allergy Clin Immunol 147:2305\u20132315e3. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.036","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR44","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/jdv.20291","volume":"39","author":"Y Pan","year":"2025","unstructured":"Pan Y, Hochgerner M, Cicho\u0144 MA et al (2025) Langerhans cells: Central players in the pathophysiology of atopic dermatitis. J Eur Acad Dermatol Venereol JEADV 39:278\u2013289. https:\/\/doi.org\/10.1111\/jdv.20291","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR45","doi-asserted-by":"publisher","first-page":"e170706","DOI":"10.1172\/JCI170706","volume":"133","author":"D-M Yu","year":"2023","unstructured":"Yu D-M, Zhao J, Lee EE et al (2023) GLUT3 promotes macrophage signaling and function via RAS-mediated endocytosis in atopic dermatitis and wound healing. J Clin Invest 133:e170706. https:\/\/doi.org\/10.1172\/JCI170706","journal-title":"J Clin Invest"},{"key":"9198_CR46","doi-asserted-by":"publisher","first-page":"eaao6923","DOI":"10.1126\/sciimmunol.aao6923","volume":"3","author":"N Malhotra","year":"2018","unstructured":"Malhotra N, Leyva-Castillo JM, Jadhav U et al (2018) ROR\u03b1-expressing T regulatory cells restrain allergic skin inflammation. Sci Immunol 3:eaao6923. https:\/\/doi.org\/10.1126\/sciimmunol.aao6923","journal-title":"Sci Immunol"},{"key":"9198_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jdermsci.2024.03.007","volume":"114","author":"B Wang","year":"2024","unstructured":"Wang B, Yu Z, Liu J et al (2024) IL-4-induced decrease in both the number and CTLA-4 expression of Treg impairs suppression of Th2 type inflammation in severe atopic dermatitis. J Dermatol Sci 114:54\u201363. https:\/\/doi.org\/10.1016\/j.jdermsci.2024.03.007","journal-title":"J Dermatol Sci"},{"key":"9198_CR48","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.3390\/ijms21155382","volume":"21","author":"M Furue","year":"2020","unstructured":"Furue M (2020) Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis. Int J Mol Sci 21:5382. https:\/\/doi.org\/10.3390\/ijms21155382","journal-title":"Int J Mol Sci"},{"key":"9198_CR49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cytogfr.2025.12.009","volume":"87","author":"MV Souto-Silva","year":"2026","unstructured":"Souto-Silva MV, Bispo ECI, de Oliveira NN et al (2026) The cytokine-skin barrier axis in health and disease. Cytokine Growth Factor Rev 87:113\u2013123. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.12.009","journal-title":"Cytokine Growth Factor Rev"},{"key":"9198_CR50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jdermsci.2021.01.005","volume":"101","author":"M Tohyama","year":"2021","unstructured":"Tohyama M, Matsumoto A, Tsuda T et al (2021) Suppression of IL-17A-induced CCL20 production by cytokine inducible SH2-containing protein 1 in epidermal keratinocytes. J Dermatol Sci 101:202\u2013209. https:\/\/doi.org\/10.1016\/j.jdermsci.2021.01.005","journal-title":"J Dermatol Sci"},{"key":"9198_CR51","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.jid.2023.12.018","volume":"144","author":"K Bier","year":"2024","unstructured":"Bier K, Senajova Z, Henrion F et al (2024) IL-26 Potentiates Type 2 Skin Inflammation in the Presence of IL-1\u03b2. J Invest Dermatol 144:1544\u20131556e9. https:\/\/doi.org\/10.1016\/j.jid.2023.12.018","journal-title":"J Invest Dermatol"},{"key":"9198_CR52","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.7150\/ijbs.93843","volume":"20","author":"C Yue","year":"2024","unstructured":"Yue C, Hu Y, Yu J et al (2024) IL-38 Aggravates Atopic Dermatitis via Facilitating Migration of Langerhans cells. Int J Biol Sci 20:3094\u20133112. https:\/\/doi.org\/10.7150\/ijbs.93843","journal-title":"Int J Biol Sci"},{"key":"9198_CR53","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.3390\/ijms22147393","volume":"22","author":"T Hou","year":"2021","unstructured":"Hou T, Tsang MS-M, Kan LL-Y et al (2021) IL-37 Targets TSLP-Primed Basophils to Alleviate Atopic Dermatitis. Int J Mol Sci 22:7393. https:\/\/doi.org\/10.3390\/ijms22147393","journal-title":"Int J Mol Sci"},{"key":"9198_CR54","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jaci.2025.07.025","volume":"156","author":"L B\u00e4hler","year":"2025","unstructured":"B\u00e4hler L, Sch\u00e4rli S, Luther F et al (2025) IL-18 in atopic dermatitis\u2014a multifaceted driver of skin inflammation. J Allergy Clin Immunol 156:1160\u20131172. https:\/\/doi.org\/10.1016\/j.jaci.2025.07.025","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR55","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41401-020-0412-8","volume":"41","author":"S-J Park","year":"2020","unstructured":"Park S-J, Im D-S (2020) Blockage of sphingosine-1-phosphate receptor 2 attenuates 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice. Acta Pharmacol Sin 41:1487\u20131496. https:\/\/doi.org\/10.1038\/s41401-020-0412-8","journal-title":"Acta Pharmacol Sin"},{"key":"9198_CR56","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.alit.2022.04.003","volume":"71","author":"M Tominaga","year":"2022","unstructured":"Tominaga M, Takamori K (2022) Peripheral itch sensitization in atopic dermatitis. Allergol Int 71:265\u2013277. https:\/\/doi.org\/10.1016\/j.alit.2022.04.003","journal-title":"Allergol Int"},{"key":"9198_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.03.010","author":"M Steinhoff","year":"2022","unstructured":"Steinhoff M, Ahmad F, Pandey A et al (2022) Neuroimmune communication regulating pruritus in atopic dermatitis. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2022.03.010","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR58","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jaci.2025.05.011","volume":"156","author":"MK Jha","year":"2025","unstructured":"Jha MK, Han Y, Liu Z et al (2025) Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch. J Allergy Clin Immunol 156:1066\u20131081e12. https:\/\/doi.org\/10.1016\/j.jaci.2025.05.011","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR59","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jaci.2025.06.031","volume":"156","author":"MT Patrick","year":"2025","unstructured":"Patrick MT, Wu Y, Zhong X et al (2025) IL31 identified as a key genetic risk factor for prurigo nodularis. J Allergy Clin Immunol 156:1410\u20131413. https:\/\/doi.org\/10.1016\/j.jaci.2025.06.031","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR60","doi-asserted-by":"publisher","first-page":"10162","DOI":"10.3390\/ijms262010162","volume":"26","author":"J \u0141acwik","year":"2025","unstructured":"\u0141acwik J, Kraik K, Laska J et al (2025) IL-31\/33 Axis in Atopic Dermatitis. Int J Mol Sci 26:10162. https:\/\/doi.org\/10.3390\/ijms262010162","journal-title":"Int J Mol Sci"},{"key":"9198_CR61","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1111\/all.14791","volume":"76","author":"A Datsi","year":"2021","unstructured":"Datsi A, Steinhoff M, Ahmad F et al (2021) Interleukin-31: The itchy cytokine in inflammation and therapy. Allergy 76:2982\u20132997. https:\/\/doi.org\/10.1111\/all.14791","journal-title":"Allergy"},{"key":"9198_CR62","doi-asserted-by":"publisher","first-page":"e22334","DOI":"10.1096\/fj.202101800R","volume":"36","author":"Z Lu","year":"2022","unstructured":"Lu Z, Xiao S, Chen W et al (2022) IL-20 promotes cutaneous inflammation and peripheral itch sensation in atopic dermatitis. FASEB J Off Publ Fed Am Soc Exp Biol 36:e22334. https:\/\/doi.org\/10.1096\/fj.202101800R","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"9198_CR63","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaci.2022.11.009","volume":"151","author":"T Hashimoto","year":"2023","unstructured":"Hashimoto T, Yokozeki H, Karasuyama H, Satoh T (2023) IL-31\u2013generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin. J Allergy Clin Immunol 151:737\u2013746e6. https:\/\/doi.org\/10.1016\/j.jaci.2022.11.009","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR64","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.neuron.2025.12.039","volume":"114","author":"R Kothari","year":"2026","unstructured":"Kothari R, Dong X (2026) The neuroimmune axis: Integrating two systems to decipher itch. Neuron 114:1343\u20131361. https:\/\/doi.org\/10.1016\/j.neuron.2025.12.039","journal-title":"Neuron"},{"key":"9198_CR65","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jaci.2023.08.017","volume":"153","author":"B Kim","year":"2024","unstructured":"Kim B, Rothenberg ME, Sun X et al (2024) Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases. J Allergy Clin Immunol 153:879\u2013893. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.017","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR66","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jaci.2024.02.005","volume":"153","author":"C Bao","year":"2024","unstructured":"Bao C, Abraham SN (2024) Mast cell-sensory neuron crosstalk in allergic diseases. J Allergy Clin Immunol 153:939\u2013953. https:\/\/doi.org\/10.1016\/j.jaci.2024.02.005","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR67","doi-asserted-by":"publisher","first-page":"eadn9390","DOI":"10.1126\/science.adn9390","volume":"387","author":"AW Liu","year":"2025","unstructured":"Liu AW, Zhang YR, Chen C-S et al (2025) Scratching promotes allergic inflammation and host defense via neurogenic mast cell activation. Science 387:eadn9390. https:\/\/doi.org\/10.1126\/science.adn9390","journal-title":"Science"},{"key":"9198_CR68","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12016-025-09127-1","volume":"69","author":"W Liu","year":"2026","unstructured":"Liu W, Zhang H, Chen X et al (2026) Neuro-immune Crosstalk in Atopic Dermatitis: A Multiaxial Regulatory Network and Novel Therapeutic Perspectives. Clin Rev Allergy Immunol 69:5. https:\/\/doi.org\/10.1007\/s12016-025-09127-1","journal-title":"Clin Rev Allergy Immunol"},{"key":"9198_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2026.02.044","author":"A Honryo","year":"2026","unstructured":"Honryo A, Masuda T, Nakamizo S et al (2026) IL-31 blockade elevates thymus and activation-regulated chemokine by lifting LAMP3\u2009+\u2009CD1c+ mature dendritic cells from calcitonin gene-related peptide-calcitonin receptor-like neuroimmune suppression in atopic dermatitis. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2026.02.044","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR70","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-026-09168-0","author":"S Peng","year":"2026","unstructured":"Peng S, Honda T (2026) \u03b3\u03b4 T Cell-Mediated Neuroimmune Interactions in Skin Inflammation and Allergy. Clin Rev Allergy Immunol. https:\/\/doi.org\/10.1007\/s12016-026-09168-0","journal-title":"Clin Rev Allergy Immunol"},{"key":"9198_CR71","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s11658-025-00834-3","volume":"31","author":"Z Li","year":"2026","unstructured":"Li Z, Yu N, Feng S et al (2026) The neuro-immune insights of itch: peripheral mechanisms and central glial contributions. Cell Mol Biol Lett 31:18. https:\/\/doi.org\/10.1186\/s11658-025-00834-3","journal-title":"Cell Mol Biol Lett"},{"key":"9198_CR72","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.alit.2024.08.010","volume":"74","author":"M Kido-Nakahara","year":"2025","unstructured":"Kido-Nakahara M, Chiba T, Mizusawa Y et al (2025) Cytokine profile of the stratum corneum in atopic dermatitis lesions differs between the face and the trunk. Allergol Int Off J Jpn Soc Allergol 74:222\u2013232. https:\/\/doi.org\/10.1016\/j.alit.2024.08.010","journal-title":"Allergol Int Off J Jpn Soc Allergol"},{"key":"9198_CR73","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jaci.2020.08.041","volume":"147","author":"H He","year":"2021","unstructured":"He H, Del Duca E, Diaz A et al (2021) Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities. J Allergy Clin Immunol 147:1369\u20131380. https:\/\/doi.org\/10.1016\/j.jaci.2020.08.041","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR74","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","volume":"145","author":"LC Tsoi","year":"2020","unstructured":"Tsoi LC, Rodriguez E, St\u00f6lzl D et al (2020) Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. J Allergy Clin Immunol 145:1406\u20131415. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.047","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR75","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaci.2021.01.001","volume":"148","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Del Duca E, Pavel AB et al (2021) The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol 148:148\u2013163. https:\/\/doi.org\/10.1016\/j.jaci.2021.01.001","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR76","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1111\/all.15741","volume":"78","author":"P Facheris","year":"2023","unstructured":"Facheris P, Da Rosa JC, Pagan AD et al (2023) Age of onset defines two distinct profiles of atopic dermatitis in adults. Allergy 78:2202\u20132214. https:\/\/doi.org\/10.1111\/all.15741","journal-title":"Allergy"},{"key":"9198_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2026.04.010","author":"D Liu","year":"2026","unstructured":"Liu D, Del Duca E, Brunner P et al (2026) Comprehensive molecular profiling of Hispanic, Black, Asian, and White patients with atopic dermatitis via tape strip RNA sequencing and serum proteomics. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2026.04.010","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072701","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Maurelli M, Calabrese L et al (2023) Overview of atopic dermatitis in different ethnic groups. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12072701","journal-title":"J Clin Med"},{"key":"9198_CR79","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jaci.2021.09.015","volume":"148","author":"EA Croce","year":"2021","unstructured":"Croce EA, Levy ML, Adamson AS, Matsui EC (2021) Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations. J Allergy Clin Immunol 148:1104\u20131111. https:\/\/doi.org\/10.1016\/j.jaci.2021.09.015","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR80","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/all.15150","volume":"77","author":"A Lef\u00e8vre-Utile","year":"2022","unstructured":"Lef\u00e8vre-Utile A, Saichi M, Ol\u00e1h P et al (2022) Transcriptome-based identification of novel endotypes in adult atopic dermatitis. Allergy 77:1486\u20131498. https:\/\/doi.org\/10.1111\/all.15150","journal-title":"Allergy"},{"key":"9198_CR81","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaci.2020.06.012","volume":"147","author":"L M\u00f6bus","year":"2021","unstructured":"M\u00f6bus L, Rodriguez E, Harder I et al (2021) Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J Allergy Clin Immunol 147:213\u2013223. https:\/\/doi.org\/10.1016\/j.jaci.2020.06.012","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR82","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1111\/jdv.19256","volume":"37","author":"J Zhou","year":"2023","unstructured":"Zhou J, Liang G, Liu L et al (2023) Single-cell RNA-seq reveals abnormal differentiation of keratinocytes and increased inflammatory differentiated keratinocytes in atopic dermatitis. J Eur Acad Dermatol Venereol JEADV 37:2336\u20132348. https:\/\/doi.org\/10.1111\/jdv.19256","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR83","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/jdv.19932","volume":"38","author":"M Fonfara","year":"2024","unstructured":"Fonfara M, Hartmann J, St\u00f6lzl D et al (2024) Stratum corneum and microbial biomarkers precede and characterize childhood atopic dermatitis. J Eur Acad Dermatol Venereol JEADV 38:1769\u20131775. https:\/\/doi.org\/10.1111\/jdv.19932","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR84","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/bjd\/ljad240","volume":"189","author":"S Weidinger","year":"2023","unstructured":"Weidinger S, Bieber T, Cork MJ et al (2023) Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol 189:531\u2013539. https:\/\/doi.org\/10.1093\/bjd\/ljad240","journal-title":"Br J Dermatol"},{"key":"9198_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.031","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Blauvelt A, Papp KA et al (2025) Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.031","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR86","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/jdv.20877","volume":"39","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Chovatiya R, Merola JF et al (2025) Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab. J Eur Acad Dermatol Venereol JEADV 39:2113\u20132120. https:\/\/doi.org\/10.1111\/jdv.20877","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR87","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(25)01865-3","volume":"407","author":"E Guttman-Yassky","year":"2026","unstructured":"Guttman-Yassky E, Kabashima K, Worm M et al (2026) Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. Lancet 407:53\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(25)01865-3","journal-title":"Lancet"},{"key":"9198_CR88","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01303-z","author":"M Gooderham","year":"2024","unstructured":"Gooderham M, Guttman-Yassky E, Igawa K et al (2024) Rocatinlimab improves patient-reported outcomes in adults with moderate-to-severe atopic dermatitis: results from a double-blind placebo-controlled phase 2b study. Dermatol Ther. https:\/\/doi.org\/10.1007\/s13555-024-01303-z","journal-title":"Dermatol Ther"},{"key":"9198_CR89","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","volume":"401","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Simpson EL, Reich K et al (2023) An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet 401:204\u2013214. https:\/\/doi.org\/10.1016\/S0140-6736(22)02037-2","journal-title":"Lancet"},{"key":"9198_CR90","unstructured":"Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials - Kyowa Kirin https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2026\/e20260303_01.html. Accessed 20 June 2026"},{"key":"9198_CR91","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1111\/all.15432","volume":"77","author":"E Berdyshev","year":"2022","unstructured":"Berdyshev E, Goleva E, Bissonnette R et al (2022) Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy 77:3388\u20133397. https:\/\/doi.org\/10.1111\/all.15432","journal-title":"Allergy"},{"key":"9198_CR92","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2023.12.027","volume":"153","author":"J Clabbers","year":"2024","unstructured":"Clabbers J, Boesjes C, Spekhorst L et al (2024) Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis. J Allergy Clin Immunol 153:1155\u20131161e4. https:\/\/doi.org\/10.1016\/j.jaci.2023.12.027","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR93","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2024.08.005","volume":"155","author":"LA Beck","year":"2025","unstructured":"Beck LA, Muraro A, Boguniewicz M et al (2025) Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 155:135\u2013143. https:\/\/doi.org\/10.1016\/j.jaci.2024.08.005","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR94","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2025.05.001","volume":"156","author":"Y Chen","year":"2025","unstructured":"Chen Y, Tian Y, Liu S et al (2025) Dupilumab-induced inhibition of myeloid dendritic cell function via TIM-3\u2013TGF-\u03b21 feedback loop in treatment of atopic dermatitis. J Allergy Clin Immunol 156:719\u2013733. https:\/\/doi.org\/10.1016\/j.jaci.2025.05.001","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR95","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1111\/all.16265","volume":"79","author":"S Yun-Chen Tsai","year":"2024","unstructured":"Yun-Chen Tsai S, Gaffin JM, Hawryluk EB et al (2024) Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: a population-based cohort study. Allergy 79:2748\u20132758. https:\/\/doi.org\/10.1111\/all.16265","journal-title":"Allergy"},{"key":"9198_CR96","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.jaci.2023.08.024","volume":"152","author":"S Traidl","year":"2023","unstructured":"Traidl S, Harries L, Kienlin P et al (2023) Dupilumab strengthens herpes simplex virus type 1\u2013specific immune responses in atopic dermatitis. J Allergy Clin Immunol 152:1460\u20131469e5. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.024","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR97","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1111\/jdv.17964","volume":"36","author":"L Potestio","year":"2022","unstructured":"Potestio L, Napolitano M, Bennardo L et al (2022) Atopic dermatitis exacerbation after Covid-19 vaccination in Dupilumab-treated patients. J Eur Acad Dermatol Venereol JEADV 36:e409\u2013e411. https:\/\/doi.org\/10.1111\/jdv.17964","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR98","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40257-024-00859-y","volume":"25","author":"AS Paller","year":"2024","unstructured":"Paller AS, Siegfried EC, Simpson EL et al (2024) Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. Am J Clin Dermatol 25:655\u2013668. https:\/\/doi.org\/10.1007\/s40257-024-00859-y","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR99","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s40257-025-00952-w","volume":"26","author":"RG Langley","year":"2025","unstructured":"Langley RG, Gherardi G, Coleman A et al (2025) The Safety Data of Dupilumab for the Treatment of Moderate\u2013to\u2013Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults. Am J Clin Dermatol 26:981\u20131002. https:\/\/doi.org\/10.1007\/s40257-025-00952-w","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR100","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/bjd\/ljae289","volume":"191","author":"A Li","year":"2024","unstructured":"Li A, Musters AH, Hyseni A et al (2024) Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-centre cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. Br J Dermatol 191:1012\u20131013. https:\/\/doi.org\/10.1093\/bjd\/ljae289","journal-title":"Br J Dermatol"},{"key":"9198_CR101","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","volume":"20","author":"LF Eichenfield","year":"2019","unstructured":"Eichenfield LF, Bieber T, Beck LA et al (2019) Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. Am J Clin Dermatol 20:443\u2013456. https:\/\/doi.org\/10.1007\/s40257-019-00445-7","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR102","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Beck LA, Blauvelt A et al (2020) Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 182:1120\u20131135. https:\/\/doi.org\/10.1111\/bjd.18434","journal-title":"Br J Dermatol"},{"key":"9198_CR103","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/bjd\/ljag052","volume":"194","author":"C Zhou","year":"2026","unstructured":"Zhou C, Zhao Y, Zhu G et al (2026) Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial. Br J Dermatol 194:1067\u20131076. https:\/\/doi.org\/10.1093\/bjd\/ljag052","journal-title":"Br J Dermatol"},{"key":"9198_CR104","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaad.2024.07.1447","volume":"91","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zhang L, Zhang J (2024) Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol 91:984\u2013986. https:\/\/doi.org\/10.1016\/j.jaad.2024.07.1447","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR105","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/bjd\/ljaf455","volume":"194","author":"M Zhao","year":"2026","unstructured":"Zhao M, Xu Z, Wu L et al (2026) Safety and efficacy of stapokibart, an anti-interleukin-4 receptor \u03b1 monoclonal antibody, in children aged 6\u201311\u2005years with moderate-to-severe atopic dermatitis: an open-label single-arm phase Ib\/IIa trial. Br J Dermatol 194:621\u2013628. https:\/\/doi.org\/10.1093\/bjd\/ljaf455","journal-title":"Br J Dermatol"},{"key":"9198_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.11.047","author":"LA Beck","year":"2023","unstructured":"Beck LA, Bieber T, Weidinger S et al (2023) Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.047","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR107","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/all.16108","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Kabashima K, Staumont-Salle D et al (2024) Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy 79:1560\u20131572. https:\/\/doi.org\/10.1111\/all.16108","journal-title":"Allergy"},{"key":"9198_CR108","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jaad.2025.09.034","volume":"94","author":"T Hagino","year":"2026","unstructured":"Hagino T, Uchiyama A, Kosaka K et al (2026) A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: Systemic therapy-na\u00efve versus systemic therapy-experienced patients. J Am Acad Dermatol 94:321\u2013322. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.034","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR109","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/all.15811","volume":"78","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Guttman-Yassky E, Eichenfield LF et al (2023) Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition. Allergy 78:2875\u20132891. https:\/\/doi.org\/10.1111\/all.15811","journal-title":"Allergy"},{"key":"9198_CR110","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/all.16414","volume":"80","author":"C Dekkers","year":"2025","unstructured":"Dekkers C, Zuithoff N, Bakker D et al (2025) Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels. Allergy 80:1060\u20131073. https:\/\/doi.org\/10.1111\/all.16414","journal-title":"Allergy"},{"key":"9198_CR111","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jaad.2025.07.040","volume":"93","author":"T Hagino","year":"2025","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N (2025) Effectiveness of tralokinumab for upadacitinib-refractory atopic dermatitis: 48-week retrospective study. J Am Acad Dermatol 93:1332\u20131334. https:\/\/doi.org\/10.1016\/j.jaad.2025.07.040","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR112","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/bjd\/ljaf309","volume":"194","author":"K Reich","year":"2026","unstructured":"Reich K, Langley RG, Silvestre Salvador JF et al (2026) Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5\u2005years: an integrated analysis of eight clinical trials. Br J Dermatol 194:225\u2013235. https:\/\/doi.org\/10.1093\/bjd\/ljaf309","journal-title":"Br J Dermatol"},{"key":"9198_CR113","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaci.2022.01.028","volume":"150","author":"Y Miron","year":"2022","unstructured":"Miron Y, Miller PE, Hughes C et al (2022) Mechanistic insights into the antipruritic effects of lebrikizumab, an anti\u2013IL-13 mAb. J Allergy Clin Immunol 150:690\u2013700. https:\/\/doi.org\/10.1016\/j.jaci.2022.01.028","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR114","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF et al (2020) Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0079","journal-title":"JAMA Dermatol"},{"key":"9198_CR115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206714","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D et al (2023) Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2206714","journal-title":"N Engl J Med"},{"key":"9198_CR116","doi-asserted-by":"publisher","unstructured":"Simpson EL, Gooderham M, Wollenberg A et al (2023) Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol 182\u2013191. https:\/\/doi.org\/10.1001\/jamadermatol.2022.5534","DOI":"10.1001\/jamadermatol.2022.5534"},{"key":"9198_CR117","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad022","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E et al (2023) Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. https:\/\/doi.org\/10.1093\/bjd\/ljad022","journal-title":"Br J Dermatol"},{"key":"9198_CR118","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/bjd\/ljae394","volume":"192","author":"N Katoh","year":"2025","unstructured":"Katoh N, Tanaka A, Takahashi H et al (2025) Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J). Br J Dermatol 192:597\u2013610. https:\/\/doi.org\/10.1093\/bjd\/ljae394","journal-title":"Br J Dermatol"},{"key":"9198_CR119","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s13555-025-01614-9","volume":"16","author":"A Abraheem","year":"2026","unstructured":"Abraheem A, Sebastian N, Kreeshan FC et al (2026) Lebrikizumab for the Treatment of Moderate to Severe Atopic Eczema: Real-World Experience from a Tertiary Centre. Dermatol Ther 16:647\u2013652. https:\/\/doi.org\/10.1007\/s13555-025-01614-9","journal-title":"Dermatol Ther"},{"key":"9198_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70442","author":"LF van der Gang","year":"2026","unstructured":"van der Gang LF, Zuithoff NPA, Haeck IM et al (2026) Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay. J Eur Acad Dermatol Venereol JEADV. https:\/\/doi.org\/10.1111\/jdv.70442","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR121","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.3390\/jcm14144960","volume":"14","author":"Y-S Kim","year":"2025","unstructured":"Kim Y-S (2025) Comparative Efficacy and Safety of Tralokinumab and Dupilumab in Moderate-to-Severe Atopic Dermatitis: A Narrative Review. J Clin Med 14:4960. https:\/\/doi.org\/10.3390\/jcm14144960","journal-title":"J Clin Med"},{"key":"9198_CR122","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/ijd.70027","volume":"65","author":"L Potestio","year":"2026","unstructured":"Potestio L, Patruno C, Del Gaudio M et al (2026) Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study. Int J Dermatol 65:299\u2013306. https:\/\/doi.org\/10.1111\/ijd.70027","journal-title":"Int J Dermatol"},{"key":"9198_CR123","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.20873","volume":"186","author":"K Kabashima","year":"2022","unstructured":"Kabashima K, Matsumura T, Komazaki H et al (2022) Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol 186:642\u2013651. https:\/\/doi.org\/10.1111\/bjd.20873","journal-title":"Br J Dermatol"},{"key":"9198_CR124","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ (2022) Nemolizumab: First Approval. Drugs 82:1143\u20131150. https:\/\/doi.org\/10.1007\/s40265-022-01741-z","journal-title":"Drugs"},{"key":"9198_CR125","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/bjd\/ljae458","volume":"192","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Katsunuma T, Nagano Y et al (2025) Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6\u201312\u2005years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study. Br J Dermatol 192:837\u2013844. https:\/\/doi.org\/10.1093\/bjd\/ljae458","journal-title":"Br J Dermatol"},{"key":"9198_CR126","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","volume":"389","author":"SG Kwatra","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ et al (2023) Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. N Engl J Med 389:1579\u20131589. https:\/\/doi.org\/10.1056\/NEJMoa2301333","journal-title":"N Engl J Med"},{"key":"9198_CR127","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jaci.2024.02.016","volume":"153","author":"BS Kim","year":"2024","unstructured":"Kim BS (2024) Learning from nemolizumab: A promising therapy for prurigo nodularis. J Allergy Clin Immunol 153:1548\u20131549. https:\/\/doi.org\/10.1016\/j.jaci.2024.02.016","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR128","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/bjd\/ljaf166","volume":"193","author":"AM Drucker","year":"2025","unstructured":"Drucker AM, Walwyn C, Chu C et al (2025) Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis. Br J Dermatol 193:548\u2013552. https:\/\/doi.org\/10.1093\/bjd\/ljaf166","journal-title":"Br J Dermatol"},{"key":"9198_CR129","doi-asserted-by":"publisher","unstructured":"Pink AE, Houghton J, White H et al (2026) Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis. Dermatol Ther 1347\u20131365. https:\/\/doi.org\/10.1007\/s13555-025-01647-0","DOI":"10.1007\/s13555-025-01647-0"},{"key":"9198_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.05.080","author":"M-L Sun","year":"2026","unstructured":"Sun M-L, Wang S-W, Gao Y-Q et al (2026) Real-world safety of nemolizumab: a pharmacovigilance analysis using the FDA adverse event reporting system (FAERS). J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2026.05.080","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR131","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf259","author":"H Kristyanto","year":"2025","unstructured":"Kristyanto H, Rey Torre S, Cunney A et al (2025) The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis. Br J Dermatol. https:\/\/doi.org\/10.1093\/bjd\/ljaf259","journal-title":"Br J Dermatol"},{"key":"9198_CR132","doi-asserted-by":"publisher","first-page":"e1211","DOI":"10.1111\/jdv.19195","volume":"37","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Bahadori L, Brooks L et al (2023) Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial. J Eur Acad Dermatol Venereol 37:e1211\u2013e1214. https:\/\/doi.org\/10.1111\/jdv.19195","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9198_CR133","doi-asserted-by":"publisher","first-page":"e70090","DOI":"10.1002\/clt2.70090","volume":"15","author":"CE Whetstone","year":"2025","unstructured":"Whetstone CE, Cusack RP, Price EL et al (2025) Benralizumab Depletes IL-5R\u03b1\u2010Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis. Clin Transl Allergy 15:e70090. https:\/\/doi.org\/10.1002\/clt2.70090","journal-title":"Clin Transl Allergy"},{"key":"9198_CR134","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","volume":"87","author":"VY Shi","year":"2022","unstructured":"Shi VY, Bhutani T, Fonacier L et al (2022) Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol 87:351\u2013358. https:\/\/doi.org\/10.1016\/j.jaad.2022.04.009","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR135","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1111\/all.16512","volume":"80","author":"AS Paller","year":"2025","unstructured":"Paller AS, Eichenfield LF, Irvine AD et al (2025) Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis. Allergy 80:2213\u20132224. https:\/\/doi.org\/10.1111\/all.16512","journal-title":"Allergy"},{"key":"9198_CR136","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A et al (2022) Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet Lond Engl 400:273\u2013282. https:\/\/doi.org\/10.1016\/S0140-6736(22)01199-0","journal-title":"Lancet Lond Engl"},{"key":"9198_CR137","doi-asserted-by":"publisher","unstructured":"St\u00e4nder S, Kwatra SG, Silverberg JI et al (2023) Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial. Am J Clin Dermatol 97\u2013107. https:\/\/doi.org\/10.1007\/s40257-022-00738-4","DOI":"10.1007\/s40257-022-00738-4"},{"key":"9198_CR138","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/jdv.19254","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, Silverberg JI, Papp KA et al (2023) Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol JEADV 37:2047\u20132055. https:\/\/doi.org\/10.1111\/jdv.19254","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR139","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70439","author":"MJ Gooderham","year":"2026","unstructured":"Gooderham MJ, Silverberg JI, De Bruin-Weller M et al (2026) Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years. J Eur Acad Dermatol Venereol JEADV. https:\/\/doi.org\/10.1111\/jdv.70439","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR140","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.19280","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, Silverberg JI, Papp KA et al (2023) Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol JEADV 37:2056\u20132066. https:\/\/doi.org\/10.1111\/jdv.19280","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR141","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/all.16495","volume":"80","author":"Z Li","year":"2025","unstructured":"Li Z, Wang Y, Wu Y et al (2025) Real-World Efficacy and Safety of Abrocitinib in Chinese Atopic Dermatitis Patients: A Single-Center Prospective Study. Allergy 80:1417\u20131427. https:\/\/doi.org\/10.1111\/all.16495","journal-title":"Allergy"},{"key":"9198_CR142","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10552-011-9872-y","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Nosbaum A et al (2024) Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure. Am J Clin Dermatol 25:639\u2013654. https:\/\/doi.org\/10.1007\/s10552-011-9872-y","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR143","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jaip.2025.02.040","volume":"13","author":"MJ Cork","year":"2025","unstructured":"Cork MJ, Deleuran M, Geng B et al (2025) Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age. J Allergy Clin Immunol Pract 13:1164\u20131175e2. https:\/\/doi.org\/10.1016\/j.jaip.2025.02.040","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9198_CR144","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jaci.2022.09.023","volume":"26","author":"AD Irvine","year":"2025","unstructured":"Irvine AD, Prajapati VH, Guttman-Yassky E et al (2025) Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. Am J Clin Dermatol 26:1003\u20131016. https:\/\/doi.org\/10.1016\/j.jaci.2022.09.023","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00589-4","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M et al (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(21)00589-4","journal-title":"Lancet"},{"key":"9198_CR146","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamadermatol.2024.3696","volume":"160","author":"AS Paller","year":"2024","unstructured":"Paller AS, Mendes-Bastos P, Siegfried E et al (2024) Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks. JAMA Dermatol 160:1304\u20131313. https:\/\/doi.org\/10.1001\/jamadermatol.2024.3696","journal-title":"JAMA Dermatol"},{"key":"9198_CR147","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jaci.2021.07.036","volume":"149","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, de Bruin-Weller M, Bieber T et al (2022) Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J Allergy Clin Immunol 149:977\u2013987e14. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.036","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR148","doi-asserted-by":"publisher","unstructured":"Paller AS, Ladizinski B, Mendes-Bastos P et al (2023) Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol 526\u2013535. https:\/\/doi.org\/10.1001\/jamadermatol.2023.0391","DOI":"10.1001\/jamadermatol.2023.0391"},{"key":"9198_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.033","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Ladizinski B, Prajapati VH et al (2023) Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2023.05.033","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR150","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40257-023-00798-0","volume":"24","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Ortoncelli M, Schena D et al (2023) Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation. Am J Clin Dermatol 24:953\u2013961. https:\/\/doi.org\/10.1007\/s40257-023-00798-0","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR151","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jaad.2025.01.052","volume":"92","author":"T Hagino","year":"2025","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N (2025) A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: Systemic therapy-naive versus -experienced patients. J Am Acad Dermatol 92:1049\u20131055. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.052","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR152","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL et al (2021) Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol 157:1047\u20131055. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023","journal-title":"JAMA Dermatol"},{"key":"9198_CR153","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/jdv.19581","volume":"38","author":"AR Schl\u00f6sser","year":"2024","unstructured":"Schl\u00f6sser AR, Boeijink N, Olydam J et al (2024) Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort. J Eur Acad Dermatol Venereol JEADV 38:384\u2013392. https:\/\/doi.org\/10.1111\/jdv.19581","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.06.007","author":"T Hagino","year":"2026","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N (2026) Three-year real-world outcomes of upadacitinib treatment for atopic dermatitis: Systemic therapy-na\u00efve versus -experienced patients. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2026.06.007","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.02.100","author":"T Hagino","year":"2026","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N (2026) A 144-week real-world outcomes of upadacitinib 30\u00a0mg for atopic dermatitis in poor responders to 15\u00a0mg. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2026.02.100","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR156","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/jdv.20674","volume":"40","author":"CG Bunick","year":"2026","unstructured":"Bunick CG, Irvine AD, Silverberg JI et al (2026) Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years. J Eur Acad Dermatol Venereol JEADV 40:856\u2013866. https:\/\/doi.org\/10.1111\/jdv.20674","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.04.046","author":"A Joshi","year":"2025","unstructured":"Joshi A, Gawey L, Rahman M et al (2025) Postmarketing safety analysis of upadacitinib in atopic dermatitis: a Food and Drug Administration adverse reporting system review of boxed warning-related adverse events. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2025.04.046","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR158","doi-asserted-by":"publisher","unstructured":"Torrelo A, Rewerska B, Galimberti M et al (2023) Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol 23\u201332. https:\/\/doi.org\/10.1093\/bjd\/ljad096","DOI":"10.1093\/bjd\/ljad096"},{"key":"9198_CR159","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21630","author":"T Bieber","year":"2022","unstructured":"Bieber T, Reich K, Paul C et al (2022) Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.21630","journal-title":"Br J Dermatol"},{"key":"9198_CR160","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour J-P, Spelman L et al (2020) Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 183:242\u2013255. https:\/\/doi.org\/10.1111\/bjd.18898","journal-title":"Br J Dermatol"},{"key":"9198_CR161","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Forman S, Silverberg JI et al (2021) Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol 85:62\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.028","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR162","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Silverberg JI, Nemoto O et al (2019) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80:913\u2013921e9. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.018","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR163","doi-asserted-by":"publisher","unstructured":"Reich K, Kabashima K, Peris K et al (2020) Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol 1333\u20131343. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3260","DOI":"10.1001\/jamadermatol.2020.3260"},{"key":"9198_CR164","doi-asserted-by":"publisher","unstructured":"Malekan M, Rahmatpour Rokni G, Gholizadeh N et al (2026) Efficacy and safety of baricitinib versus azathioprine, both combined with topical corticosteroids, in patients with moderate-to-severe atopic dermatitis: a single-centre randomized open-label trial. Br J Dermatol 461\u2013469. https:\/\/doi.org\/10.1093\/bjd\/ljaf456","DOI":"10.1093\/bjd\/ljaf456"},{"key":"9198_CR165","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/bjd\/ljac057","volume":"188","author":"K Reich","year":"2023","unstructured":"Reich K, Simpson E, Wollenberg A et al (2023) Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. Br J Dermatol 188:208\u2013217. https:\/\/doi.org\/10.1093\/bjd\/ljac057","journal-title":"Br J Dermatol"},{"key":"9198_CR166","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.19426","volume":"38","author":"S Yoon","year":"2024","unstructured":"Yoon S, Kim K, Shin K et al (2024) The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol JEADV 38:52\u201361. https:\/\/doi.org\/10.1111\/jdv.19426","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR167","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00228-022-03400-4","volume":"78","author":"C Alves","year":"2022","unstructured":"Alves C, Penedones A, Mendes D, Batel Marques F (2022) The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis. Eur J Clin Pharmacol 78:1923\u20131933. https:\/\/doi.org\/10.1007\/s00228-022-03400-4","journal-title":"Eur J Clin Pharmacol"},{"key":"9198_CR168","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M et al (2023) Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis 82:119\u2013129. https:\/\/doi.org\/10.1136\/ard-2022-222259","journal-title":"Ann Rheum Dis"},{"key":"9198_CR169","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 386:316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"9198_CR170","doi-asserted-by":"publisher","first-page":"1443704","DOI":"10.3389\/fimmu.2024.1443704","volume":"15","author":"R Poto","year":"2024","unstructured":"Poto R, Cristinziano L, Criscuolo G et al (2024) The JAK1\/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells. Front Immunol 15:1443704. https:\/\/doi.org\/10.3389\/fimmu.2024.1443704","journal-title":"Front Immunol"},{"key":"9198_CR171","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40257-024-00855-2","volume":"25","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield LF, Simpson EL, Papp K et al (2024) Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. Am J Clin Dermatol 25:669\u2013683. https:\/\/doi.org\/10.1007\/s40257-024-00855-2","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR172","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40257-024-00901-z","volume":"26","author":"EL Simpson","year":"2025","unstructured":"Simpson EL, Augustin M, Tha\u00e7i D et al (2025) Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies. Am J Clin Dermatol 26:121\u2013137. https:\/\/doi.org\/10.1007\/s40257-024-00901-z","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR173","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-023-00840-1","volume":"25","author":"W Hu","year":"2024","unstructured":"Hu W, Thornton M, Livingston RA (2024) Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year. Am J Clin Dermatol 25:327\u2013332. https:\/\/doi.org\/10.1007\/s40257-023-00840-1","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR174","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/bjd\/ljaf482","volume":"194","author":"D Wang","year":"2026","unstructured":"Wang D, Wu J, Guo Q et al (2026) Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II\/III clinical trial. Br J Dermatol 194:629\u2013639. https:\/\/doi.org\/10.1093\/bjd\/ljaf482","journal-title":"Br J Dermatol"},{"key":"9198_CR175","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-025-02086-1","author":"F Xiong","year":"2026","unstructured":"Xiong F, Zhou B, Huang S et al (2026) Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions. Inflammopharmacology. https:\/\/doi.org\/10.1007\/s10787-025-02086-1","journal-title":"Inflammopharmacology"},{"key":"9198_CR176","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jamadermatol.2025.0982","volume":"161","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Gooderham M, Yang B et al (2025) Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial. JAMA Dermatol 161:688\u2013697. https:\/\/doi.org\/10.1001\/jamadermatol.2025.0982","journal-title":"JAMA Dermatol"},{"key":"9198_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.015","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A et al (2020) Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.015","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR178","doi-asserted-by":"publisher","unstructured":"Nakagawa H, Nemoto O, Igarashi A et al (2019) Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol 1575\u20131583. https:\/\/doi.org\/10.1016\/j.jaci.2019.08.004","DOI":"10.1016\/j.jaci.2019.08.004"},{"key":"9198_CR179","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","volume":"85","author":"H Nakagawa","year":"2021","unstructured":"Nakagawa H, Nemoto O, Igarashi A et al (2021) Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol 85:854\u2013862. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.014","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2026.04.008","author":"S Yoshihara","year":"2026","unstructured":"Yoshihara S, Yoshihara S, Miyamoto M et al (2026) Efficacy and safety of delgocitinib ointment in combination with topical corticosteroids for remission induction in pediatric patients with atopic dermatitis: A 4-week, randomized, open-label, parallel-group study in Japan. Allergol Int Off J Jpn Soc Allergol. https:\/\/doi.org\/10.1016\/j.alit.2026.04.008","journal-title":"Allergol Int Off J Jpn Soc Allergol"},{"key":"9198_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2023.04.003","author":"H Nakagawa","year":"2024","unstructured":"Nakagawa H, Igarashi A, Saeki H et al (2024) Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: a phase 3, open-label, and long-term study. Allergol Int. https:\/\/doi.org\/10.1016\/j.alit.2023.04.003","journal-title":"Allergol Int"},{"key":"9198_CR182","unstructured":"DailyMed - ANZUPGO- delgocitinib cream. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a59bf36e-6f04-4b47-b385-8040c95f040c. Accessed 20 July 2026"},{"key":"9198_CR183","unstructured":"(2025) Overview | Delgocitinib for treating moderate to severe chronic hand eczema | Guidance | NICE. https:\/\/www.nice.org.uk\/guidance\/ta1107. Accessed 20 July 2026"},{"key":"9198_CR184","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","volume":"73","author":"LL Levy","year":"2015","unstructured":"Levy LL, Urban J, King BA (2015) Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 73:395\u2013399. https:\/\/doi.org\/10.1016\/j.jaad.2015.06.045","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR185","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.3390\/cells10113176","volume":"10","author":"N Fern\u00e1ndez-Gallego","year":"2021","unstructured":"Fern\u00e1ndez-Gallego N, S\u00e1nchez-Madrid F, Cibrian D (2021) Role of AHR Ligands in Skin Homeostasis and Cutaneous Inflammation. Cells 10:3176. https:\/\/doi.org\/10.3390\/cells10113176","journal-title":"Cells"},{"key":"9198_CR186","doi-asserted-by":"publisher","first-page":"9412","DOI":"10.3390\/ijms21249412","volume":"21","author":"YH Vu","year":"2020","unstructured":"Vu YH, Hashimoto-Hachiya A, Takemura M et al (2020) IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis. Int J Mol Sci 21:9412. https:\/\/doi.org\/10.3390\/ijms21249412","journal-title":"Int J Mol Sci"},{"key":"9198_CR187","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jaad.2025.05.1391","volume":"93","author":"R Bissonnette","year":"2025","unstructured":"Bissonnette R, Stein Gold L, Kircik L et al (2025) Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. J Am Acad Dermatol 93:707\u2013714. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1391","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR188","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Eichenfield LF, Hebert AA et al (2024) Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol 91:457\u2013465. https:\/\/doi.org\/10.1016\/j.jaad.2024.05.023","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR189","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40257-025-00929-9","volume":"26","author":"AS Paller","year":"2025","unstructured":"Paller AS, Hebert AA, Gonzalez ME et al (2025) Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis. Am J Clin Dermatol 26:449\u2013456. https:\/\/doi.org\/10.1007\/s40257-025-00929-9","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR190","doi-asserted-by":"publisher","first-page":"7910","DOI":"10.3390\/ijms25147910","volume":"25","author":"G Tsuji","year":"2024","unstructured":"Tsuji G, Yumine A, Kawamura K et al (2024) Difamilast, a Topical Phosphodiesterase 4 Inhibitor, Produces Soluble ST2 via the AHR\u2013NRF2 Axis in Human Keratinocytes. Int J Mol Sci 25:7910. https:\/\/doi.org\/10.3390\/ijms25147910","journal-title":"Int J Mol Sci"},{"key":"9198_CR191","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jid.2023.09.272","volume":"144","author":"K Takahashi","year":"2024","unstructured":"Takahashi K, Miyake K, Ito J et al (2024) Topical Application of a PDE4 Inhibitor Ameliorates Atopic Dermatitis through Inhibition of Basophil IL-4 Production. J Invest Dermatol 144:1048\u20131057e8. https:\/\/doi.org\/10.1016\/j.jid.2023.09.272","journal-title":"J Invest Dermatol"},{"key":"9198_CR192","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.3390\/ijms23073467","volume":"23","author":"N Zeze","year":"2022","unstructured":"Zeze N, Kido-Nakahara M, Tsuji G et al (2022) Role of ERK Pathway in the Pathogenesis of Atopic Dermatitis and Its Potential as a Therapeutic Target. Int J Mol Sci 23:3467. https:\/\/doi.org\/10.3390\/ijms23073467","journal-title":"Int J Mol Sci"},{"key":"9198_CR193","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaad.2021.10.027","volume":"86","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ito K, Yokota D, Tsubouchi H (2022) Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 86:607\u2013614. https:\/\/doi.org\/10.1016\/j.jaad.2021.10.027","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR194","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjd.20655","volume":"186","author":"H Saeki","year":"2022","unstructured":"Saeki H, Baba N, Ito K et al (2022) Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial. Br J Dermatol 186:40\u201349. https:\/\/doi.org\/10.1111\/bjd.20655","journal-title":"Br J Dermatol"},{"key":"9198_CR195","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s13555-025-01581-1","volume":"16","author":"H Saeki","year":"2026","unstructured":"Saeki H, Ohya Y, Baba N et al (2026) A Phase 3, Long-Term, Open-Label Study of Difamilast Ointment to Evaluate Efficacy and Safety in Japanese Infants with Atopic Dermatitis. Dermatol Ther 16:339\u2013352. https:\/\/doi.org\/10.1007\/s13555-025-01581-1","journal-title":"Dermatol Ther"},{"key":"9198_CR196","doi-asserted-by":"publisher","unstructured":"Nakahara T, Murota H, Matsukawa M et al (2024) Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis. Dermatol Ther 2905\u20132916. https:\/\/doi.org\/10.1007\/s13555-024-01282-1","DOI":"10.1007\/s13555-024-01282-1"},{"key":"9198_CR197","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaad.2023.02.064","volume":"89","author":"M Kim","year":"2023","unstructured":"Kim M, Del Duca E, Cheng J et al (2023) Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin. J Am Acad Dermatol 89:283\u2013292. https:\/\/doi.org\/10.1016\/j.jaad.2023.02.064","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR198","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jaad.2023.10.057","volume":"90","author":"AB Fishbein","year":"2024","unstructured":"Fishbein AB, Mukherji J, Demczuk M et al (2024) Biomarkers of response to topical crisaborole in patients with mild\/moderate pediatric atopic dermatitis from minimally invasive tape strip transcriptome. J Am Acad Dermatol 90:629\u2013632. https:\/\/doi.org\/10.1016\/j.jaad.2023.10.057","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR199","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00780-w","author":"LF Eichenfield","year":"2023","unstructured":"Eichenfield LF, Gower RG, Xu J et al (2023) Once-daily crisaborole ointment, 2%, as a long-term maintenance treatment in patients aged\u2009\u2265\u20093 months with mild-to-moderate atopic dermatitis: a 52-week clinical study. Am J Clin Dermatol. https:\/\/doi.org\/10.1007\/s40257-023-00780-w","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR200","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s13555-025-01371-9","volume":"15","author":"RB Warren","year":"2025","unstructured":"Warren RB, Weiss A, Felding J, Sommer MOA (2025) Population Pharmacokinetic-Pharmacodynamic (popPK\/PD) Relationship of Orismilast, A Potent and Selective PDE4B\/D Inhibitor, in Atopic Dermatitis. Dermatol Ther 15:831\u2013839. https:\/\/doi.org\/10.1007\/s13555-025-01371-9","journal-title":"Dermatol Ther"},{"key":"9198_CR201","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/jdv.18818","volume":"37","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, French LE, Warren RB et al (2023) Pharmacology of orismilast, a potent and selective PDE4 inhibitor. J Eur Acad Dermatol Venereol JEADV 37:721\u2013729. https:\/\/doi.org\/10.1111\/jdv.18818","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR202","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/bjd\/ljae507","volume":"192","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Eichenfield LF, Blauvelt A et al (2025) Orismilast, a phosphodiesterase 4B\/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS). Br J Dermatol 192:995\u20131006. https:\/\/doi.org\/10.1093\/bjd\/ljae507","journal-title":"Br J Dermatol"},{"key":"9198_CR203","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/bjd\/ljaf042","volume":"192","author":"C Alves","year":"2025","unstructured":"Alves C (2025) Orismilast for moderate-to-severe atopic dermatitis: the potential therapeutic value of a new oral pharmacological alternative. Br J Dermatol 192:965\u2013966. https:\/\/doi.org\/10.1093\/bjd\/ljaf042","journal-title":"Br J Dermatol"},{"key":"9198_CR204","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","volume":"80","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, Parnes JR, She D et al (2019) Tezepelumab, an anti\u2013thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. J Am Acad Dermatol 80:1013\u20131021. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.059","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR205","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/bjd\/ljaf156","volume":"193","author":"L Kircik","year":"2025","unstructured":"Kircik L, Tsianakas A, Valenzuela F et al (2025) Efficacy and safety of rilzabrutinib in patients with moderate-to-severe atopic dermatitis: 16-week results from a proof-of-concept phase II clinical trial. Br J Dermatol 193:424\u2013433. https:\/\/doi.org\/10.1093\/bjd\/ljaf156","journal-title":"Br J Dermatol"},{"key":"9198_CR206","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","volume":"35","author":"MZ Popiela","year":"2021","unstructured":"Popiela MZ, Barbara R, Turnbull AMJ et al (2021) Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye Lond Engl 35:3277\u20133284. https:\/\/doi.org\/10.1038\/s41433-020-01379-9","journal-title":"Eye Lond Engl"},{"key":"9198_CR207","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40259-024-00668-z","volume":"38","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Li J-Y, Yang B et al (2024) Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial. BioDrugs Clin Immunother Biopharm Gene Ther 38:681\u2013689. https:\/\/doi.org\/10.1007\/s40259-024-00668-z","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"9198_CR208","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40257-021-00602-x","volume":"22","author":"B King","year":"2021","unstructured":"King B, Maari C, Lain E et al (2021) Extended Safety Analysis of Baricitinib 2\u00a0mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. Am J Clin Dermatol 22:395\u2013405. https:\/\/doi.org\/10.1007\/s40257-021-00602-x","journal-title":"Am J Clin Dermatol"},{"key":"9198_CR209","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/1346-8138.15173","volume":"47","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A et al (2020) Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol 47:114\u2013120. https:\/\/doi.org\/10.1111\/1346-8138.15173","journal-title":"J Dermatol"},{"key":"9198_CR210","doi-asserted-by":"publisher","first-page":"110958","DOI":"10.1016\/j.intimp.2023.110958","volume":"124","author":"Y Lu","year":"2023","unstructured":"Lu Y, Sun Y, Peng Y et al (2023) Inhibition of gasdermin D (GSDMD) as a promising therapeutic approach for atopic dermatitis. Int Immunopharmacol 124:110958. https:\/\/doi.org\/10.1016\/j.intimp.2023.110958","journal-title":"Int Immunopharmacol"},{"key":"9198_CR211","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jid.2020.05.095","volume":"141","author":"CT Turner","year":"2021","unstructured":"Turner CT, Zeglinski MR, Richardson KC et al (2021) Granzyme B Contributes to Barrier Dysfunction in Oxazolone-Induced Skin Inflammation through E-Cadherin and FLG Cleavage. J Invest Dermatol 141:36\u201347. https:\/\/doi.org\/10.1016\/j.jid.2020.05.095","journal-title":"J Invest Dermatol"},{"key":"9198_CR212","doi-asserted-by":"publisher","first-page":"8237","DOI":"10.3390\/ijms22158237","volume":"22","author":"C-C Yang","year":"2021","unstructured":"Yang C-C, Hung Y-L, Ko W-C et al (2021) Effect of Neferine on DNCB-Induced Atopic Dermatitis in HaCaT Cells and BALB\/c Mice. Int J Mol Sci 22:8237. https:\/\/doi.org\/10.3390\/ijms22158237","journal-title":"Int J Mol Sci"},{"key":"9198_CR213","doi-asserted-by":"publisher","first-page":"118439","DOI":"10.1016\/j.jep.2024.118439","volume":"333","author":"Z Huang","year":"2024","unstructured":"Huang Z, Fan B, Mao W et al (2024) Topical application of Artemisia annua L. essential oil ameliorates 2,4-dintrochlorobenzene-induced atopic dermatitis in mice. J Ethnopharmacol 333:118439. https:\/\/doi.org\/10.1016\/j.jep.2024.118439","journal-title":"J Ethnopharmacol"},{"key":"9198_CR214","doi-asserted-by":"publisher","first-page":"154200","DOI":"10.1016\/j.phymed.2022.154200","volume":"102","author":"D-D Hou","year":"2022","unstructured":"Hou D-D, Gu Y-J, Wang D-C et al (2022) Therapeutic effects of myricetin on atopic dermatitis in vivo and in vitro. Phytomedicine 102:154200. https:\/\/doi.org\/10.1016\/j.phymed.2022.154200","journal-title":"Phytomedicine"},{"key":"9198_CR215","doi-asserted-by":"publisher","first-page":"136064","DOI":"10.1016\/j.ijbiomac.2024.136064","volume":"281","author":"Z Wang","year":"2024","unstructured":"Wang Z, Chen H, Wang Y et al (2024) Recombinant filaggrin-2 improves skin barrier function and attenuates ultraviolet B (UVB) irradiation-induced epidermal barrier disruption. Int J Biol Macromol 281:136064. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.136064","journal-title":"Int J Biol Macromol"},{"key":"9198_CR216","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s13287-025-04649-z","volume":"16","author":"D Park","year":"2025","unstructured":"Park D, Kim JH, Yang H et al (2025) Mesenchymal stem cell-derived extracellular vesicles exert Th1-mediated anti-inflammatory effects via miR-146a\/NF-\u03baB pathway: comparison with dupilumab in a mouse model of atopic dermatitis. Stem Cell Res Ther 16:496. https:\/\/doi.org\/10.1186\/s13287-025-04649-z","journal-title":"Stem Cell Res Ther"},{"key":"9198_CR217","doi-asserted-by":"publisher","first-page":"szaf030","DOI":"10.1093\/stcltm\/szaf030","volume":"14","author":"D Park","year":"2025","unstructured":"Park D, Kim JH, Kim JE et al (2025) Effects of MSC-derived extracellular vesicles and dupilumab on the spleen and skin in a house dust mite-induced atopic dermatitis model. Stem Cells Transl Med 14:szaf030. https:\/\/doi.org\/10.1093\/stcltm\/szaf030","journal-title":"Stem Cells Transl Med"},{"key":"9198_CR218","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13287-023-03365-w","volume":"14","author":"C Hua","year":"2023","unstructured":"Hua C, Liang Q, Chen S et al (2023) Human umbilical cord mesenchymal stem cell treatment alleviates symptoms in an atopic dermatitis-like mouse model. Stem Cell Res Ther 14:147. https:\/\/doi.org\/10.1186\/s13287-023-03365-w","journal-title":"Stem Cell Res Ther"},{"key":"9198_CR219","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12951-022-01728-8","volume":"20","author":"J Kim","year":"2022","unstructured":"Kim J, Lee SK, Jung M et al (2022) Extracellular vesicles from IFN-\u03b3-primed mesenchymal stem cells repress atopic dermatitis in mice. J Nanobiotechnol 20:526. https:\/\/doi.org\/10.1186\/s12951-022-01728-8","journal-title":"J Nanobiotechnol"},{"key":"9198_CR220","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/cells9030680","volume":"9","author":"K-O Shin","year":"2020","unstructured":"Shin K-O, Ha DH, Kim JO et al (2020) Exosomes from Human Adipose Tissue-Derived Mesenchymal Stem Cells Promote Epidermal Barrier Repair by Inducing de Novo Synthesis of Ceramides in Atopic Dermatitis. Cells 9:680. https:\/\/doi.org\/10.3390\/cells9030680","journal-title":"Cells"},{"key":"9198_CR221","doi-asserted-by":"publisher","first-page":"e70121","DOI":"10.1002\/jev2.70121","volume":"14","author":"K-O Shin","year":"2025","unstructured":"Shin K-O, Lee JH, Chae S et al (2025) Small EVs From Adipose-Derived MSCs Modulate Epidermal Barrier and Inflammation Via Sphingosine-1-Phosphate Signaling Pathway. J Extracell Vesicles 14:e70121. https:\/\/doi.org\/10.1002\/jev2.70121","journal-title":"J Extracell Vesicles"},{"key":"9198_CR222","doi-asserted-by":"publisher","first-page":"e0292050","DOI":"10.1371\/journal.pone.0292050","volume":"19","author":"YJ Roh","year":"2024","unstructured":"Roh YJ, Choi YH, Shin SH et al (2024) Adipose tissue-derived exosomes alleviate particulate matter-induced inflammatory response and skin barrier damage in atopic dermatitis-like triple-cell model. PLoS ONE 19:e0292050. https:\/\/doi.org\/10.1371\/journal.pone.0292050","journal-title":"PLoS ONE"},{"key":"9198_CR223","doi-asserted-by":"publisher","first-page":"e2304862","DOI":"10.1002\/smll.202304862","volume":"20","author":"MJ Byun","year":"2024","unstructured":"Byun MJ, Seo HS, Lee J et al (2024) Biofunctional Inorganic Layered Double Hydroxide Nanohybrid Enhances Immunotherapeutic Effect on Atopic Dermatitis Treatment. Small 20:e2304862. https:\/\/doi.org\/10.1002\/smll.202304862","journal-title":"Small"},{"key":"9198_CR224","doi-asserted-by":"publisher","first-page":"e2409121","DOI":"10.1002\/smll.202409121","volume":"21","author":"W Zhang","year":"2025","unstructured":"Zhang W, Lei J, Jiang P et al (2025) Double-Layered Microneedle Patch Integrated with Multifunctional Nanoparticles and Live Bacteria for Long-Term Treatment of Atopic Dermatitis. Small 21:e2409121. https:\/\/doi.org\/10.1002\/smll.202409121","journal-title":"Small"},{"key":"9198_CR225","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s12016-025-09057-y","volume":"68","author":"H You","year":"2025","unstructured":"You H, Liang Y (2025) Atopic Dermatitis: The Relationship Between Immune Mediators and Skin Lipid Barrier. Clin Rev Allergy Immunol 68:49. https:\/\/doi.org\/10.1007\/s12016-025-09057-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"9198_CR226","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.molmed.2019.04.001","volume":"25","author":"N Bhattacharya","year":"2019","unstructured":"Bhattacharya N, Sato WJ, Kelly A et al (2019) Epidermal Lipids: Key Mediators of Atopic Dermatitis Pathogenesis. Trends Mol Med 25:551\u2013562. https:\/\/doi.org\/10.1016\/j.molmed.2019.04.001","journal-title":"Trends Mol Med"},{"key":"9198_CR227","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/all.15569","volume":"78","author":"H Yin","year":"2023","unstructured":"Yin H, Qiu Z, Zhu R et al (2023) Dysregulated lipidome of sebum in patients with atopic dermatitis. Allergy 78:1524\u20131537. https:\/\/doi.org\/10.1111\/all.15569","journal-title":"Allergy"},{"key":"9198_CR228","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jaci.2025.08.033","volume":"157","author":"S Wasserer","year":"2026","unstructured":"Wasserer S, Litman T, Hebsgaard J et al (2026) Neutralizing IL-22RA1 improves histologic and molecular alterations associated with atopic dermatitis pathogenesis. J Allergy Clin Immunol 157:653\u2013665. https:\/\/doi.org\/10.1016\/j.jaci.2025.08.033","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR229","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/all.14606","volume":"76","author":"N Ottman","year":"2021","unstructured":"Ottman N, Barrientos-Somarribas M, Fyhrquist N et al (2021) Microbial and transcriptional differences elucidate atopic dermatitis heterogeneity across skin sites. Allergy 76:1173\u20131187. https:\/\/doi.org\/10.1111\/all.14606","journal-title":"Allergy"},{"key":"9198_CR230","doi-asserted-by":"publisher","first-page":"zsad276","DOI":"10.1093\/sleep\/zsad276","volume":"47","author":"MK Arif","year":"2024","unstructured":"Arif MK, Zee PC, Paller AS et al (2024) Severe atopic dermatitis, sleep disturbance, and low light exposure. Sleep 47:zsad276. https:\/\/doi.org\/10.1093\/sleep\/zsad276","journal-title":"Sleep"},{"key":"9198_CR231","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.2147\/CCID.S424343","volume":"16","author":"N Sun","year":"2023","unstructured":"Sun N, Dai D, Deng S et al (2023) Bioinformatics Integrative Analysis of Circadian Rhythms Effects on Atopic Dermatitis and Dendritic Cells. Clin Cosmet Investig Dermatol 16:2919\u20132930. https:\/\/doi.org\/10.2147\/CCID.S424343","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"9198_CR232","doi-asserted-by":"publisher","first-page":"adv35427","DOI":"10.2340\/actadv.v104.35427","volume":"104","author":"X Sang","year":"2024","unstructured":"Sang X, Lu J, Tan L et al (2024) The Circadian Rhythm of Itching among 241 Adults with Atopic Dermatitis: A Cross-sectional Study. Acta Derm Venereol 104:adv35427. https:\/\/doi.org\/10.2340\/actadv.v104.35427","journal-title":"Acta Derm Venereol"},{"key":"9198_CR233","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jaad.2018.04.020","volume":"85","author":"AB Fishbein","year":"2021","unstructured":"Fishbein AB, Lin B, Beaumont J et al (2021) Nocturnal movements in children with atopic dermatitis have a timing pattern: A case-control study. J Am Acad Dermatol 85:474\u2013476. https:\/\/doi.org\/10.1016\/j.jaad.2018.04.020","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR234","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1016\/j.jid.2022.03.021","volume":"142","author":"H Yeo","year":"2022","unstructured":"Yeo H, Ahn SS, Jung E et al (2022) Transcription Factor EGR1 Regulates the Expression of the Clock Gene PER2 under IL-4 Stimulation in Human Keratinocytes. J Invest Dermatol 142:2677\u20132686e9. https:\/\/doi.org\/10.1016\/j.jid.2022.03.021","journal-title":"J Invest Dermatol"},{"key":"9198_CR235","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4062\/biomolther.2020.215","volume":"29","author":"VP Annamneedi","year":"2021","unstructured":"Annamneedi VP, Park JW, Lee GS, Kang TJ (2021) Cell Autonomous Circadian Systems and Their Relation to Inflammation. Biomol Ther 29:31\u201340. https:\/\/doi.org\/10.4062\/biomolther.2020.215","journal-title":"Biomol Ther"},{"key":"9198_CR236","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jaci.2023.11.926","volume":"153","author":"G Ratley","year":"2024","unstructured":"Ratley G, Zeldin J, Chaudhary PP et al (2024) The circadian metabolome of atopic dermatitis. J Allergy Clin Immunol 153:1148\u20131154. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.926","journal-title":"J Allergy Clin Immunol"},{"key":"9198_CR237","doi-asserted-by":"publisher","first-page":"e0318360","DOI":"10.1371\/journal.pone.0318360","volume":"20","author":"M Yeom","year":"2025","unstructured":"Yeom M, Jeon K, Ryu D-H et al (2025) Time-of-day dependent promotion of keratinocyte differentiation by Cinnamomum cassia bark extract through the p38 MAPK Pathway. PLoS ONE 20:e0318360. https:\/\/doi.org\/10.1371\/journal.pone.0318360","journal-title":"PLoS ONE"},{"key":"9198_CR238","doi-asserted-by":"publisher","unstructured":"N\u00e9meth V, Horv\u00e1th S, Kiny\u00f3 \u00c1 et al (2021) Expression Patterns of Clock Gene mRNAs and Clock Proteins in Human Psoriatic Skin Samples. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms23010121","DOI":"10.3390\/ijms23010121"},{"key":"9198_CR239","doi-asserted-by":"publisher","unstructured":"Borghi A, Flacco ME, Bocchi C et al (2025) Time of Day of Biological Treatment Administration and Outcomes in Atopic Dermatitis: Results from a Preliminary Retrospective Study. Dermat Contact Atopic Occup Drug 490\u2013499. https:\/\/doi.org\/10.1089\/derm.2024.0282","DOI":"10.1089\/derm.2024.0282"},{"key":"9198_CR240","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.12.026","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Rosmarin D, de Bruin-Weller M et al (2025) The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.026","journal-title":"J Am Acad Dermatol"},{"key":"9198_CR241","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1111\/jdv.19391","volume":"37","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Silverberg JI, Tha\u00e7i D et al (2023) Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial. J Eur Acad Dermatol Venereol JEADV 37:2558\u20132568. https:\/\/doi.org\/10.1111\/jdv.19391","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"9198_CR242","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm M, Simpson EL, Tha\u00e7i D et al (2020) Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol 156:131\u2013143. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3617","journal-title":"JAMA Dermatol"},{"key":"9198_CR243","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184:437\u2013449. https:\/\/doi.org\/10.1111\/bjd.19574","journal-title":"Br J Dermatol"},{"key":"9198_CR244","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163495","author":"H Han","year":"2023","unstructured":"Han H, Cummings S, Shade K-T et al (2023) Cellular mechanisms and effects of IL-4 receptor blockade in experimental conjunctivitis evoked by skin inflammation. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.163495","journal-title":"JCI Insight"},{"key":"9198_CR245","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M et al (2021) The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 6:402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1","journal-title":"Signal Transduct Target Ther"},{"key":"9198_CR246","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI et al (2021) Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med 384:1101\u20131112. https:\/\/doi.org\/10.1056\/NEJMoa2019380","journal-title":"N Engl J Med"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09198-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09198-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09198-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T20:02:04Z","timestamp":1788033724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09198-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":246,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9198"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09198-8","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"72"}}